Connect your AI

Exagen Inc. XGN Payments for finance leases

Payments for finance leases at other companies

Aurinia PharmaceuticalsAUPH

$3.65M+31.8%

Agilent TechnologiesA

——

Other financials

Income statement

Revenue$17.3M+11.7%

Gross profit$10.2M+11.9%

Operating income-$3.4M-1.5%

Net income-$4.0M-5.7%

EPS (diluted)-$0.17+15.0%

Balance sheet

Cash & equivalents$21.7M+90.6%

Total debt$27.1M+15.8%

Total equity$14.4M+125%

Total assets$52.0M+28.9%

Cash flow

Operating cash flow-$10.4M+2.4%

CapEx$228.0K+102%

Free cash flow-$10.6M+1.3%

Valuation

Market cap$112.34M-26.5%

Enterprise value$117.78M-20.3%

P/S1.6×-1.0×

Profitability

Gross margin58.3%-1.0pp

Operating margin-20.6%-2.9pp

Net margin-29.5%+2.5pp

FCF margin-27.5%—

Returns & leverage

Return on equity-193.6%+355pp

Debt / equity1.9×-1.8×

Current ratio3.5×+1.1×

Where this comes from

Reported directly by Exagen Inc. in its filing.

Tagged under the XBRL concept us-gaap:FinanceLeasePrincipalPayments.

The official record: Exagen Inc.’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Exagen Inc.'s payments for finance leases.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Exagen Inc.'s payments for finance leases?: Exagen Inc. (XGN) reported payments for finance leases of $189K in Q1 2026.
How has Exagen Inc.'s payments for finance leases changed year-over-year?: Exagen Inc.'s payments for finance leases increased by 110.0% year-over-year, from $90K to $189K.
What is the long-term trend for Exagen Inc.'s payments for finance leases?: Over 4 years (2021 to 2025), Exagen Inc.'s payments for finance leases has grown at a -1.5% compound annual growth rate (CAGR), from $525K to $494K.
What does payments for finance leases mean?: Principal payments on finance lease obligations, reducing the lease liability on the balance sheet.